Business UpdateMay 12, 2026, 04:01 PM
Cytokinetics to Participate in RBC Capital Markets Global Healthcare Conference
AI Summary
Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 19, 2026, at 3:35 PM ET in New York, NY, with a live webcast and 90-day replay available on the company's investor relations website. Cytokinetics is a biopharmaceutical company specializing in cardiovascular diseases, with its approved drug MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy and other investigational medicines in its pipeline.
Key Highlights
- Cytokinetics management to participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference.
- The event is scheduled for Tuesday, May 19, 2026, at 3:35 PM Eastern Time in New York, NY.
- A live webcast will be available via the Investors & Media section of the Cytokinetics website.
- Webcast replays will be archived on the company's website for 90 days post-event.
- Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on muscle biology.
- The company's MYQORZO (aficamten) is approved in the U.S., Europe, and China for obstructive HCM.
- Cytokinetics is also developing omecamtiv mecarbil and ulacamten for heart failure.
Price Impact
More from CYTK